Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer
This study has been completed.
Information provided by (Responsible Party):
First received: November 21, 2007
Last updated: February 4, 2013
Last verified: February 2013
To evaluate Arimidex 6 month therapy as an adjuvant treatment in postmenopausal patients with advanced breast cancer in whom a partial or complete response or stabilized disease were obtained with first line chemotherapy, by tumoral response assessment.
Advanced Breast Cancer
||Time Perspective: Prospective
||ARIMIDEX Study ( Non-interventional Study to Evaluate Arimidex in Adjuvant Therapy in Partial or Complete Response or Stabilized Disease After First Line Chemotherapy in Postmenopausal Women With Advanced Breast Cancer)
| Study Start Date:
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Postmenopausal patients with advanced breast cancer in whom a partial or complete response or stabilized disease were obtained with first line chemotherapy, by tumoral response assessment.
- Patients to be included in the program are that ones according to the indications specified in the Romanian anastrozole (Arimidex) approved SmPC (attached to the protocol)and who are already treated with anastrozole for at least 1 month before inclusion in this program/non-interventional study.
- Patients not to be included in the programme: patients who have a known hypersensitivity to anastrozole (Arimidex®) or any of its excipients.
No Contacts or Locations Provided
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 21, 2007
||February 4, 2013
||Romania: National Medicines Agency
Keywords provided by AstraZeneca:
Advanced breast cancer
Advanced breast cancer in postmenopausal women
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 10, 2014
Neoplasms by Site
Antineoplastic Agents, Hormonal
Molecular Mechanisms of Pharmacological Action